Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial

PURPOSE: Interferon is approved for adjuvant treatment of patients with stage IIb/III melanoma. The toxicity and uncertainty regarding survival benefits of interferon have qualified its acceptance, despite significant durable relapse prevention in a fraction of patients. Predictive biomarkers that w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gogas, Helen, Dafni, Urania, Koon, Henry, Spyropoulou-Vlachou, Maria, Metaxas, Yannis, Buchbinder, Elizabeth, Pectasides, Eirini, Tsoutsos, Dimosthenis, Polyzos, Aristidis, Stratigos, Alexandros, Markopoulos, Christos, Panagiotou, Petros, Fountzilas, George, Castana, Ourania, Skarlos, Pantelis, Atkins, Michael B, Kirkwood, John M
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2010
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2988721/
https://ncbi.nlm.nih.gov/pubmed/21044351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-8-108
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados